Drug exposure and psoriasis vulgaris : Case-control and case-crossover studies
Intake of drugs is considered a risk factor for psoriasis. The aim of this study was to investigate the association between drugs and psoriasis. A case-control study including 110 patients who were hospitalized for extensive psoriasis was performed. A control group (n = 515) was defined as patients...
Gespeichert in:
| Veröffentlicht in: | Acta dermato-venereologica 2005-01, Vol.85 (4), p.299-303 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 303 |
|---|---|
| container_issue | 4 |
| container_start_page | 299 |
| container_title | Acta dermato-venereologica |
| container_volume | 85 |
| creator | COHEN, Arnon D BONNEH, Dan Y REUVENI, Haim VARDY, Daniel A NAGGAN, Lechaim HALEVY, Sima |
| description | Intake of drugs is considered a risk factor for psoriasis. The aim of this study was to investigate the association between drugs and psoriasis. A case-control study including 110 patients who were hospitalized for extensive psoriasis was performed. A control group (n = 515) was defined as patients who had undergone elective surgery. A case-crossover study included 98 patients with psoriasis. Exposure to drugs was assessed during a hazard period (3 months before hospitalization) and compared to a control period in the patient's past. Data on drug sales were extracted by data mining techniques. Multivariate analyses were performed by logistic regression and conditional logistic regression. In the case-control study, psoriasis was associated with benzodiazepines (OR 6.9), organic nitrates (OR 5.0), angiotensin-converting enzyme (ACE) inhibitors (OR 4.0) and non-steroidal anti-inflammatory drugs (NSAIDs) (OR 3.7). In the case-crossover study, psoriasis was associated with ACE inhibitors (OR 9.9), beta-blockers (OR 9.9), dipyrone (OR 4.9) and NSAIDs (OR 2.1). Extensive psoriasis may be associated with intake of ACE inhibitors, NSAIDs or beta-blockers. |
| doi_str_mv | 10.1080/00015550510032823 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_00015550510032823</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16191849</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-359b74ca3c13d3ffa01a23bb8aeeea4b6c334a6519e97b4f7488c8bfa2dd4fbb3</originalsourceid><addsrcrecordid>eNplkMlOwzAQhi0EoqXwAFxQLhwDHi-Jww21bFIFFzhHY8eugtIm8jQVvD3pIoHEabbvH838jF0CvwFu-C3nHLTWXAPnUhghj9gYMg2p4Do_ZuPtPB0APWJnRJ9DKTSYUzaCDAowqhiz11nsF4n_6lrqo09wVSUdtbFGqinZ9M0C45DcJVMkn7p2tY5ts6PcrhFbonbjY0Lrvqo9nbOTgA35i0OcsI_Hh_fpczp_e3qZ3s9TJ3OxTqUubK4cSgeykiEgBxTSWoPee1Q2c1IqHD4pfJFbFXJljDM2oKgqFayVEwb7vbsLog9lF-slxu8SeLn1pvznzaC52mu63i599as4mDEA1wcAyWETIq5cTX-4wnCTZfIHwrNs2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Drug exposure and psoriasis vulgaris : Case-control and case-crossover studies</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>COHEN, Arnon D ; BONNEH, Dan Y ; REUVENI, Haim ; VARDY, Daniel A ; NAGGAN, Lechaim ; HALEVY, Sima</creator><creatorcontrib>COHEN, Arnon D ; BONNEH, Dan Y ; REUVENI, Haim ; VARDY, Daniel A ; NAGGAN, Lechaim ; HALEVY, Sima</creatorcontrib><description>Intake of drugs is considered a risk factor for psoriasis. The aim of this study was to investigate the association between drugs and psoriasis. A case-control study including 110 patients who were hospitalized for extensive psoriasis was performed. A control group (n = 515) was defined as patients who had undergone elective surgery. A case-crossover study included 98 patients with psoriasis. Exposure to drugs was assessed during a hazard period (3 months before hospitalization) and compared to a control period in the patient's past. Data on drug sales were extracted by data mining techniques. Multivariate analyses were performed by logistic regression and conditional logistic regression. In the case-control study, psoriasis was associated with benzodiazepines (OR 6.9), organic nitrates (OR 5.0), angiotensin-converting enzyme (ACE) inhibitors (OR 4.0) and non-steroidal anti-inflammatory drugs (NSAIDs) (OR 3.7). In the case-crossover study, psoriasis was associated with ACE inhibitors (OR 9.9), beta-blockers (OR 9.9), dipyrone (OR 4.9) and NSAIDs (OR 2.1). Extensive psoriasis may be associated with intake of ACE inhibitors, NSAIDs or beta-blockers.</description><identifier>ISSN: 0001-5555</identifier><identifier>EISSN: 1651-2057</identifier><identifier>DOI: 10.1080/00015550510032823</identifier><identifier>PMID: 16191849</identifier><identifier>CODEN: ADVEA4</identifier><language>eng</language><publisher>Uppsala: Acta dermato-venereologica</publisher><subject>Adrenergic beta-Antagonists - adverse effects ; Angiotensin-Converting Enzyme Inhibitors - adverse effects ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Biological and medical sciences ; Case-Control Studies ; Cross-Over Studies ; Dermatology ; Drug Prescriptions - statistics & numerical data ; Female ; Humans ; Italy - epidemiology ; Logistic Models ; Male ; Medical sciences ; Middle Aged ; Psoriasis - chemically induced ; Psoriasis - epidemiology ; Psoriasis - pathology ; Psoriasis. Parapsoriasis. Lichen ; Severity of Illness Index</subject><ispartof>Acta dermato-venereologica, 2005-01, Vol.85 (4), p.299-303</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-359b74ca3c13d3ffa01a23bb8aeeea4b6c334a6519e97b4f7488c8bfa2dd4fbb3</citedby><cites>FETCH-LOGICAL-c372t-359b74ca3c13d3ffa01a23bb8aeeea4b6c334a6519e97b4f7488c8bfa2dd4fbb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16980866$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16191849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>COHEN, Arnon D</creatorcontrib><creatorcontrib>BONNEH, Dan Y</creatorcontrib><creatorcontrib>REUVENI, Haim</creatorcontrib><creatorcontrib>VARDY, Daniel A</creatorcontrib><creatorcontrib>NAGGAN, Lechaim</creatorcontrib><creatorcontrib>HALEVY, Sima</creatorcontrib><title>Drug exposure and psoriasis vulgaris : Case-control and case-crossover studies</title><title>Acta dermato-venereologica</title><addtitle>Acta Derm Venereol</addtitle><description>Intake of drugs is considered a risk factor for psoriasis. The aim of this study was to investigate the association between drugs and psoriasis. A case-control study including 110 patients who were hospitalized for extensive psoriasis was performed. A control group (n = 515) was defined as patients who had undergone elective surgery. A case-crossover study included 98 patients with psoriasis. Exposure to drugs was assessed during a hazard period (3 months before hospitalization) and compared to a control period in the patient's past. Data on drug sales were extracted by data mining techniques. Multivariate analyses were performed by logistic regression and conditional logistic regression. In the case-control study, psoriasis was associated with benzodiazepines (OR 6.9), organic nitrates (OR 5.0), angiotensin-converting enzyme (ACE) inhibitors (OR 4.0) and non-steroidal anti-inflammatory drugs (NSAIDs) (OR 3.7). In the case-crossover study, psoriasis was associated with ACE inhibitors (OR 9.9), beta-blockers (OR 9.9), dipyrone (OR 4.9) and NSAIDs (OR 2.1). Extensive psoriasis may be associated with intake of ACE inhibitors, NSAIDs or beta-blockers.</description><subject>Adrenergic beta-Antagonists - adverse effects</subject><subject>Angiotensin-Converting Enzyme Inhibitors - adverse effects</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Cross-Over Studies</subject><subject>Dermatology</subject><subject>Drug Prescriptions - statistics & numerical data</subject><subject>Female</subject><subject>Humans</subject><subject>Italy - epidemiology</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Psoriasis - chemically induced</subject><subject>Psoriasis - epidemiology</subject><subject>Psoriasis - pathology</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>Severity of Illness Index</subject><issn>0001-5555</issn><issn>1651-2057</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkMlOwzAQhi0EoqXwAFxQLhwDHi-Jww21bFIFFzhHY8eugtIm8jQVvD3pIoHEabbvH838jF0CvwFu-C3nHLTWXAPnUhghj9gYMg2p4Do_ZuPtPB0APWJnRJ9DKTSYUzaCDAowqhiz11nsF4n_6lrqo09wVSUdtbFGqinZ9M0C45DcJVMkn7p2tY5ts6PcrhFbonbjY0Lrvqo9nbOTgA35i0OcsI_Hh_fpczp_e3qZ3s9TJ3OxTqUubK4cSgeykiEgBxTSWoPee1Q2c1IqHD4pfJFbFXJljDM2oKgqFayVEwb7vbsLog9lF-slxu8SeLn1pvznzaC52mu63i599as4mDEA1wcAyWETIq5cTX-4wnCTZfIHwrNs2w</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>COHEN, Arnon D</creator><creator>BONNEH, Dan Y</creator><creator>REUVENI, Haim</creator><creator>VARDY, Daniel A</creator><creator>NAGGAN, Lechaim</creator><creator>HALEVY, Sima</creator><general>Acta dermato-venereologica</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20050101</creationdate><title>Drug exposure and psoriasis vulgaris : Case-control and case-crossover studies</title><author>COHEN, Arnon D ; BONNEH, Dan Y ; REUVENI, Haim ; VARDY, Daniel A ; NAGGAN, Lechaim ; HALEVY, Sima</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-359b74ca3c13d3ffa01a23bb8aeeea4b6c334a6519e97b4f7488c8bfa2dd4fbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adrenergic beta-Antagonists - adverse effects</topic><topic>Angiotensin-Converting Enzyme Inhibitors - adverse effects</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Cross-Over Studies</topic><topic>Dermatology</topic><topic>Drug Prescriptions - statistics & numerical data</topic><topic>Female</topic><topic>Humans</topic><topic>Italy - epidemiology</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Psoriasis - chemically induced</topic><topic>Psoriasis - epidemiology</topic><topic>Psoriasis - pathology</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>COHEN, Arnon D</creatorcontrib><creatorcontrib>BONNEH, Dan Y</creatorcontrib><creatorcontrib>REUVENI, Haim</creatorcontrib><creatorcontrib>VARDY, Daniel A</creatorcontrib><creatorcontrib>NAGGAN, Lechaim</creatorcontrib><creatorcontrib>HALEVY, Sima</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta dermato-venereologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>COHEN, Arnon D</au><au>BONNEH, Dan Y</au><au>REUVENI, Haim</au><au>VARDY, Daniel A</au><au>NAGGAN, Lechaim</au><au>HALEVY, Sima</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug exposure and psoriasis vulgaris : Case-control and case-crossover studies</atitle><jtitle>Acta dermato-venereologica</jtitle><addtitle>Acta Derm Venereol</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>85</volume><issue>4</issue><spage>299</spage><epage>303</epage><pages>299-303</pages><issn>0001-5555</issn><eissn>1651-2057</eissn><coden>ADVEA4</coden><abstract>Intake of drugs is considered a risk factor for psoriasis. The aim of this study was to investigate the association between drugs and psoriasis. A case-control study including 110 patients who were hospitalized for extensive psoriasis was performed. A control group (n = 515) was defined as patients who had undergone elective surgery. A case-crossover study included 98 patients with psoriasis. Exposure to drugs was assessed during a hazard period (3 months before hospitalization) and compared to a control period in the patient's past. Data on drug sales were extracted by data mining techniques. Multivariate analyses were performed by logistic regression and conditional logistic regression. In the case-control study, psoriasis was associated with benzodiazepines (OR 6.9), organic nitrates (OR 5.0), angiotensin-converting enzyme (ACE) inhibitors (OR 4.0) and non-steroidal anti-inflammatory drugs (NSAIDs) (OR 3.7). In the case-crossover study, psoriasis was associated with ACE inhibitors (OR 9.9), beta-blockers (OR 9.9), dipyrone (OR 4.9) and NSAIDs (OR 2.1). Extensive psoriasis may be associated with intake of ACE inhibitors, NSAIDs or beta-blockers.</abstract><cop>Uppsala</cop><pub>Acta dermato-venereologica</pub><pmid>16191849</pmid><doi>10.1080/00015550510032823</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-5555 |
| ispartof | Acta dermato-venereologica, 2005-01, Vol.85 (4), p.299-303 |
| issn | 0001-5555 1651-2057 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_00015550510032823 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adrenergic beta-Antagonists - adverse effects Angiotensin-Converting Enzyme Inhibitors - adverse effects Anti-Inflammatory Agents, Non-Steroidal - adverse effects Biological and medical sciences Case-Control Studies Cross-Over Studies Dermatology Drug Prescriptions - statistics & numerical data Female Humans Italy - epidemiology Logistic Models Male Medical sciences Middle Aged Psoriasis - chemically induced Psoriasis - epidemiology Psoriasis - pathology Psoriasis. Parapsoriasis. Lichen Severity of Illness Index |
| title | Drug exposure and psoriasis vulgaris : Case-control and case-crossover studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T01%3A11%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20exposure%20and%20psoriasis%20vulgaris%20:%20Case-control%20and%20case-crossover%20studies&rft.jtitle=Acta%20dermato-venereologica&rft.au=COHEN,%20Arnon%20D&rft.date=2005-01-01&rft.volume=85&rft.issue=4&rft.spage=299&rft.epage=303&rft.pages=299-303&rft.issn=0001-5555&rft.eissn=1651-2057&rft.coden=ADVEA4&rft_id=info:doi/10.1080/00015550510032823&rft_dat=%3Cpubmed_cross%3E16191849%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16191849&rfr_iscdi=true |